HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician’s Offices & Clinics), Region - Global Forecast to 2027

Abstract
The global HPV testing and Pap test market is projected to reach USD 9.2 billion by 2027 from USD 4.9 billion in 2022, at a CAGR of 13.2% during the forecast period. Market growth is driven by factors such as increased production HPV diagnostic products and government initiatives. On the other hand, challenges associated with HPV testing and Pap test is uncertain reimbursement scenarios is the major factors hampering the growth of this market.

“The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period”

The HPV testing and Pap test market is segmented into HPV testing and Pap test. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increase in number of product approval and increased focus on reducing cancer cases are major factor contributing to the growth of this segment.

“The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period”

The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increasing funding for the prevention of cervical cancer are major factor contributing to the growth of this segment.

“The hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market, by end user, during the forecast period”

The HPV testing and Pap test market is segmented into laboratories, hospitals and physician’s offices & clinics based on end user. In 2021, the hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.

“Asia Pacific: The fastest-growing region in HPV testing and Pap test market”

The global HPV testing and Pap test market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of cervical cancer is driving the growth of the HPV testing and Pap test market in this region.

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
•By Designation: C-level - 27%, D-level - 18%, and Others - 55%
•By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
•Abbott Laboratories (US)
•Roche Diagnostics (Switzerland)
•Becton, Dickinson and Company (US)
•Hologic, Inc. (US)
•Quest Diagnostics (US)
•Qiagen N.V. (Netherland)
•Seegene, Inc. (US)
•Femasys, Inc. (US)
•Arbor Vita Corporation (US)
•Mylab Discovery Solutions Pvt. Ltd. (India)
•EverlyWell, Inc. (US)
•Nurx, Inc. (US)
•Dalrada Corporation (US)
•NeoDiagnostix (US)
•Jiangsu Mole Bioscience Co., Ltd. (China)
•Sansure Biotech Inc. (China)

Research Coverage:
This report provides a detailed picture of the global HPV testing and Pap test market. It aims at estimating the size and future growth potential of the market across different segments, such as test type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

Content
Table of Contents

1INTRODUCTION30
1.1STUDY OBJECTIVES30
1.2MARKET DEFINITION30
1.2.1INCLUSIONS AND EXCLUSIONS31
1.3MARKETS COVERED31
FIGURE 1HPV TESTING AND PAP TEST MARKET SEGMENTATION31
1.3.1YEARS CONSIDERED32
1.4CURRENCY CONSIDERED32
1.5LIMITATIONS32
1.6STAKEHOLDERS33
1.7SUMMARY OF CHANGES33
2RESEARCH METHODOLOGY34
2.1RESEARCH DATA34
2.2RESEARCH APPROACH34
FIGURE 2HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN34
2.2.1SECONDARY DATA35
2.2.1.1Key data from secondary sources35
2.2.2PRIMARY DATA36
2.2.2.1Primary sources37
2.2.2.2Key data from primary sources37
2.2.2.3Key industry insights38
2.2.2.4Breakdown of primary interviews38
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS38
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION39
2.3MARKET SIZE ESTIMATION39
2.3.1BOTTOM-UP APPROACH40
2.3.1.1Approach 1: Company revenue estimation approach40
FIGURE 5BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH40
2.3.1.2Approach 2: Presentations of companies and primary interviews40
2.3.1.3CAGR projections41
FIGURE 6CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS41
2.3.2TOP-DOWN APPROACH41
FIGURE 7HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH41
2.4MARKET BREAKDOWN AND DATA TRIANGULATION42
FIGURE 8DATA TRIANGULATION METHODOLOGY42
2.5MARKET SHARE ANALYSIS43
2.6STUDY ASSUMPTIONS43
2.7GROWTH RATE ASSUMPTIONS43
2.8RISK ASSESSMENT44
2.8.1HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT44
3EXECUTIVE SUMMARY45
FIGURE 9HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)45
FIGURE 10HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)46
FIGURE 11HPV TESTING AND PAP TEST MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)46
FIGURE 12HPV TESTING AND PAP TEST MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)47
4PREMIUM INSIGHTS48
4.1HPV TESTING AND PAP TEST MARKET OVERVIEW48
FIGURE 13RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL CANCER SCREENING TO DRIVE MARKET48
4.2HPV TESTING AND PAP TEST MARKET SHARE, BY TEST TYPE, 2022 VS. 202749
FIGURE 14HPV TESTING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD49
4.3HPV TESTING AND PAP TEST MARKET SHARE, BY APPLICATION, 2022 VS. 202749
FIGURE 15CERVICAL CANCER SCREENING SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD49
4.4HPV TESTING AND PAP TEST MARKET SHARE, BY END USER, 2022 VS. 202750
FIGURE 16HOSPITALS TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD50
4.5HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES50
FIGURE 17ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD50
5MARKET OVERVIEW51
5.1INTRODUCTION51
5.2MARKET DYNAMICS51
FIGURE 18HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES51
5.2.1DRIVERS52
5.2.1.1Rising HPV cases and subsequent increase in cervical cancer52
5.2.1.2Growing awareness of cervical cancer screening programs52
5.2.1.3Increasing R&D funding initiatives on cervical cancer prevention53
5.2.2RESTRAINTS54
5.2.2.1Growing awareness of HPV vaccination54
5.2.3OPPORTUNITIES54
5.2.3.1Regulatory guidelines for cervical cancer screening54
5.2.3.2Innovative improvements in HPV tests54
5.2.3.2.1Introduction of HPV primary screening tests55
5.2.3.2.2Technological improvements in HPV tests55
5.2.4CHALLENGES56
5.2.4.1Uncertain reimbursement scenario56
5.2.4.2Stringent regulatory & legal requirements56
5.2.4.3Operational barriers57
5.3PRICING ANALYSIS57
TABLE 1PRICE OF HPV TESTING AND PAP TEST PRODUCTS (2021)57
5.4PATENT ANALYSIS58
FIGURE 19PATENT ANALYSIS OF HPV TESTING AND PAP TEST MARKET58
5.5VALUE CHAIN ANALYSIS59
FIGURE 20VALUE CHAIN ANALYSIS OF HPV TESTING AND PAP TEST MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES59
5.6SUPPLY CHAIN ANALYSIS60
FIGURE 21HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS60
5.7ECOSYSTEM/MARKET MAP61
FIGURE 22HPV TESTING AND PAP TEST MARKET: ECOSYSTEM/MARKET MAP61
5.7.1HPV TESTING AND PAP TEST MARKET: ROLE IN ECOSYSTEM61
5.8PORTER’S FIVE FORCES ANALYSIS62
TABLE 2HPV TESTING AND PAP TEST MARKET: PORTER’S FIVE FORCES ANALYSIS62
5.8.1THREAT OF NEW ENTRANTS62
5.8.2THREAT OF SUBSTITUTES62
5.8.3BARGAINING POWER OF BUYERS62
5.8.4BARGAINING POWER OF SUPPLIERS63
5.8.5DEGREE OF COMPETITION63
5.9TRADE ANALYSIS63
5.9.1TRADE ANALYSIS FOR DIAGNOSTIC OR LABORATORY REAGENTS63
TABLE 3IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)63
TABLE 4EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)63
5.10TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES64
5.10.1REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-1964
FIGURE 23REVENUE SHIFT IN HPV TESTING AND PAP TEST MARKET64
6HPV TESTING AND PAP TEST MARKET, BY TEST TYPE65
6.1INTRODUCTION66
TABLE 5HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)66
TABLE 6HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)66
TABLE 7HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)67
TABLE 8HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)67
6.2HPV TESTING67
TABLE 9HPV TESTING MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)68
TABLE 10HPV TESTING MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)68
TABLE 11HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)68
TABLE 12HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)69
6.2.1FOLLOW-UP HPV TESTING69
6.2.1.1Irregular Pap test results to drive adoption69
TABLE 13FOLLOW-UP HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)69
TABLE 14FOLLOW-UP HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)70
6.2.2CO-TESTING70
6.2.2.1Co-testing to drive rapid detection results for cervical cancer70
TABLE 15HPV CO-TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)70
TABLE 16HPV CO-TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)71
6.2.3PRIMARY HPV TESTING71
6.2.3.1Test sensitivity and accuracy to drive segment growth71
TABLE 17PRIMARY HPV TESTING MARKET, BY REGION, 2017–2020 (USD MILLION)71
TABLE 18PRIMARY HPV TESTING MARKET, BY REGION, 2021–2027 (USD MILLION)72
6.3PAP TEST72
6.3.1RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET72
TABLE 19PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION)72
TABLE 20PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION)73
7HPV TESTING AND PAP TEST MARKET, BY APPLICATION74
7.1INTRODUCTION75
TABLE 21HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)75
TABLE 22HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)75
7.2CERVICAL CANCER SCREENING75
7.2.1RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET75
TABLE 23HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)76
TABLE 24HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)76
7.3VAGINAL CANCER SCREENING77
7.3.1LIMITED SCREENING TESTS TO RESTRAIN MARKET77
TABLE 25HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2017–2020 (USD MILLION)77
TABLE 26HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY REGION, 2021–2027 (USD MILLION)77
8HPV TESTING AND PAP TEST MARKET, BY END USER78
8.1INTRODUCTION79
TABLE 27HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)79
TABLE 28HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)79
8.2HOSPITALS79
8.2.1ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET79
TABLE 29HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2017–2020 (USD MILLION)80
TABLE 30HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION, 2021–2027 (USD MILLION)80
8.3LABORATORIES81
8.3.1INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET81
TABLE 31HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2017–2020 (USD MILLION)81
TABLE 32HPV TESTING AND PAP TEST MARKET FOR LABORATORIES, BY REGION, 2021–2027 (USD MILLION)82
8.4PHYSICIANS’ OFFICES AND CLINICS82
8.4.1RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH82
TABLE 33HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2017–2020 (USD MILLION)82
TABLE 34HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES AND CLINICS, BY REGION, 2021–2027 (USD MILLION)83
9HPV TESTING AND PAP TEST MARKET, BY REGION84
9.1INTRODUCTION85
TABLE 35HPV TESTING AND PAP TEST MARKET, BY REGION, 2017–2020 (USD MILLION)85
TABLE 36HPV TESTING AND PAP TEST MARKET, BY REGION, 2021–2027 (USD MILLION)85
9.2NORTH AMERICA86
FIGURE 24NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT87
TABLE 37NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION)87
TABLE 38NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION)88
TABLE 39NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)88
TABLE 40NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)88
TABLE 41NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)89
TABLE 42NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)89
TABLE 43NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)89
TABLE 44NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)90
TABLE 45NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)90
TABLE 46NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)90
TABLE 47NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)91
TABLE 48NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)91
9.2.1US91
9.2.1.1Rising government initiatives for cancer research to drive market91
TABLE 49US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)92
TABLE 50US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)92
TABLE 51US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)92
TABLE 52US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)93
TABLE 53US: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)93
TABLE 54US: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)93
TABLE 55US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)94
TABLE 56US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)94
TABLE 57US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)94
TABLE 58US: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)95
9.2.2CANADA95
9.2.2.1Government support in raising awareness on cervical cancer screening to support market growth95
TABLE 59CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)95
TABLE 60CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)96
TABLE 61CANADA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)96
TABLE 62CANADA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)96
TABLE 63CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)97
TABLE 64CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)97
TABLE 65CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)97
TABLE 66CANADA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)98
9.3EUROPE98
TABLE 67EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION)99
TABLE 68EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION)99
TABLE 69EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)99
TABLE 70EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)100
TABLE 71EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)100
TABLE 72EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)100
TABLE 73EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)101
TABLE 74EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)101
TABLE 75EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)101
TABLE 76EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)102
TABLE 77EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)102
TABLE 78EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)102
9.3.1GERMANY103
9.3.1.1Established healthcare infrastructure and rising government spending on cancer screening to drive market103
TABLE 79GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)103
TABLE 80GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)104
TABLE 81GERMANY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)104
TABLE 82GERMANY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)104
TABLE 83GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)105
TABLE 84GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)105
TABLE 85GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)105
TABLE 86GERMANY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)106
9.3.2UK106
9.3.2.1Rising focus on research projects for specific cancers to drive market106
TABLE 87UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)107
TABLE 88UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)107
TABLE 89UK: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)107
TABLE 90UK: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)108
TABLE 91UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)108
TABLE 92UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)108
TABLE 93UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)109
TABLE 94UK: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)109
9.3.3FRANCE109
9.3.3.1High incidence of cervical cancer and associated investments in genomics to support market growth109
TABLE 95FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)110
TABLE 96FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)110
TABLE 97FRANCE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)110
TABLE 98FRANCE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)111
TABLE 99FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)111
TABLE 100FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)111
TABLE 101FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)112
TABLE 102FRANCE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)112
9.3.4SPAIN112
9.3.4.1Increasing research on cancer diagnostics to support market growth112
TABLE 103SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)113
TABLE 104SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)113
TABLE 105SPAIN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)113
TABLE 106SPAIN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)114
TABLE 107SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)114
TABLE 108SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)114
TABLE 109SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)115
TABLE 110SPAIN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)115
9.3.5ITALY115
9.3.5.1Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to drive market115
TABLE 111ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)116
TABLE 112ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)116
TABLE 113ITALY: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)116
TABLE 114ITALY: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)117
TABLE 115ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)117
TABLE 116ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)117
TABLE 117ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)118
TABLE 118ITALY: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)118
9.3.6REST OF EUROPE118
TABLE 119REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)119
TABLE 120REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)119
TABLE 121REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)119
TABLE 122REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)120
TABLE 123REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)120
TABLE 124REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)120
TABLE 125REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)121
TABLE 126REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)121
9.4ASIA PACIFIC122
FIGURE 25ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT123
TABLE 127ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2017–2020 (USD MILLION)124
TABLE 128ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2021–2027 (USD MILLION)124
TABLE 129ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)124
TABLE 130ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)125
TABLE 131ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)125
TABLE 132ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)125
TABLE 133ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)126
TABLE 134ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)126
TABLE 135ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)126
TABLE 136ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)127
TABLE 137ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)127
TABLE 138ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)127
9.4.1CHINA128
9.4.1.1Government initiatives for cancer diagnosis and immunotherapy to support market growth128
TABLE 139CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)128
TABLE 140CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)128
TABLE 141CHINA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)129
TABLE 142CHINA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)129
TABLE 143CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)129
TABLE 144CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)130
TABLE 145CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)130
TABLE 146CHINA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)130
9.4.2JAPAN131
9.4.2.1Rising demand for technologically advanced cervical cancer screening tests to drive market131
TABLE 147JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)131
TABLE 148JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)131
TABLE 149JAPAN: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)132
TABLE 150JAPAN: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)132
TABLE 151JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)132
TABLE 152JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)133
TABLE 153JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)133
TABLE 154JAPAN: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)133
9.4.3INDIA134
9.4.3.1High cancer burden and rising pharmaceutical industry to drive market134
TABLE 155INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)134
TABLE 156INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)134
TABLE 157INDIA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)135
TABLE 158INDIA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)135
TABLE 159INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)135
TABLE 160INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)136
TABLE 161INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)136
TABLE 162INDIA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)136
9.4.4REST OF ASIA PACIFIC137
TABLE 163REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)137
TABLE 164REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)137
TABLE 165REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)138
TABLE 166REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)138
TABLE 167REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)138
TABLE 168REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)139
TABLE 169REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)139
TABLE 170REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)139
9.5LATIN AMERICA140
9.5.1RISING AWARENESS OF ADVANCED CANCER SCREENING TECHNOLOGIES TO DRIVE MARKET140
TABLE 171LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)140
TABLE 172LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)140
TABLE 173LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)141
TABLE 174LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)141
TABLE 175LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)141
TABLE 176LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)142
TABLE 177LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)142
TABLE 178LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)142
TABLE 179LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)143
TABLE 180LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)143
 
9.6MIDDLE EAST AND AFRICA143
9.6.1IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE DUE TO HIGH CANCER BURDEN TO SUPPORT MARKET GROWTH143
TABLE 181MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (USD MILLION)144
TABLE 182MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (USD MILLION)144
TABLE 183MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2017–2020 (MILLION KITS)144
TABLE 184MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2021–2027 (MILLION KITS)145
TABLE 185MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2017–2020 (USD MILLION)145
TABLE 186MIDDLE EAST AND AFRICA: HPV TESTING MARKET, BY TYPE, 2021–2027 (USD MILLION)145
TABLE 187MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2017–2020 (USD MILLION)146
TABLE 188MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2021–2027 (USD MILLION)146
TABLE 189MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2017–2020 (USD MILLION)146
TABLE 190MIDDLE EAST AND AFRICA: HPV TESTING AND PAP TEST MARKET, BY END USER, 2021–2027 (USD MILLION)147
10COMPETITIVE LANDSCAPE148
10.1OVERVIEW148
10.2STRATEGIES ADOPTED BY KEY PLAYERS148
10.2.1HPV TESTING AND PAP TEST MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS149
TABLE 191OVERVIEW OF STRATEGIES ADOPTED BY KEY HPV TESTING AND PAP TEST PLAYERS149
10.3REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS150
FIGURE 26REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS150
10.4MARKET SHARE ANALYSIS151
FIGURE 27HPV TESTING AND PAP TEST MARKET SHARE, BY KEY PLAYER (2021)151
TABLE 192HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION151
10.5COMPANY EVALUATION QUADRANT152
10.5.1LIST OF EVALUATED VENDORS152
10.5.2STARS152
10.5.3EMERGING LEADERS152
10.5.4PERVASIVE PLAYERS152
10.5.5PARTICIPANTS153
FIGURE 28HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021153
 
10.6COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)154
10.6.1PROGRESSIVE COMPANIES154
10.6.2STARTING BLOCKS154
10.6.3RESPONSIVE COMPANIES154
10.6.4DYNAMIC COMPANIES154
FIGURE 29HPV TESTING AND PAP TEST MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021155
10.7COMPETITIVE SCENARIO156
10.7.1PRODUCT LAUNCHES & APPROVALS156
TABLE 193PRODUCT LAUNCHES & APPROVALS (2020-2022)156
10.7.2DEALS157
TABLE 194DEALS (2021-2022)157
10.7.3OTHER DEVELOPMENTS157
TABLE 195OTHER DEVELOPMENTS157
11COMPANY PROFILES158
11.1KEY PLAYERS158
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1ABBOTT LABORATORIES158
TABLE 196ABBOTT LABORATORIES: BUSINESS OVERVIEW158
FIGURE 30ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)159
11.1.2ROCHE DIAGNOSTICS161
TABLE 197ROCHE DIAGNOSTICS: BUSINESS OVERVIEW161
FIGURE 31ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)162
11.1.3HOLOGIC, INC.165
TABLE 198HOLOGIC, INC.: BUSINESS OVERVIEW165
FIGURE 32HOLOGIC, INC: COMPANY SNAPSHOT (2021)166
11.1.4BECTON, DICKINSON AND COMPANY168
TABLE 199BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW168
FIGURE 33BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)169
11.1.5QUEST DIAGNOSTICS172
TABLE 200QUEST DIAGNOSTICS: BUSINESS OVERVIEW172
FIGURE 34QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2021)172
11.1.6QIAGEN N.V.174
TABLE 201QIAGEN N.V.: BUSINESS OVERVIEW174
FIGURE 35QIAGEN N.V.: COMPANY SNAPSHOT (2021)175
11.1.7SEEGENE, INC.176
TABLE 202SEEGENE, INC: BUSINESS OVERVIEW176
11.1.8FEMASYS, INC.177
TABLE 203FEMASYS, INC.: BUSINESS OVERVIEW177
11.1.9ARBOR VITA CORPORATION178
TABLE 204ARBOR VITA CORPORATION: BUSINESS OVERVIEW178
11.1.10MYLAB DISCOVERY SOLUTIONS PVT. LTD.179
TABLE 205MYLAB DISCOVERY SOLUTIONS PVT. LTD.: BUSINESS OVERVIEW179
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2OTHER PLAYERS180
11.2.1EVERLYWELL INC.180
TABLE 206EVERLYWELL INC.: COMPANY OVERVIEW180
11.2.2NURX INC.180
TABLE 207NURX INC.: COMPANY OVERVIEW180
11.2.3DALRADA CORPORATION181
TABLE 208DALRADA CORPORATION: COMPANY OVERVIEW181
11.2.4NEODIAGNOSTIX181
TABLE 209NEODIAGNOSTIX: COMPANY OVERVIEW181
11.2.5JIANGSU MOLE BIOSCIENCE CO., LTD.182
TABLE 210JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW182
11.2.6SANSURE BIOTECH INC.182
TABLE 211SANSURE BIOTECH, INC.: COMPANY OVERVIEW182
12APPENDIX183
12.1DISCUSSION GUIDE183
12.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL186
12.3CUSTOMIZATION OPTIONS188
12.4RELATED REPORTS188
12.5AUTHOR DETAILS189